EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2023

Summary

Multiple sclerosis (MS) is an inflammatory disease in which the myelin sheaths around the axons of the brain and spinal cord are damaged, leading to demyelination and a wide range of signs and symptoms. MS affects 2.5 million people worldwide each year and is the most debilitating neurological disease in young adults.

GlobalData epidemiologists expect that the number of prevalent and incident cases of MS will increase during the forecast period (2013-2023) in the 10MM. In 2013, GlobalData epidemiologists forecast that there were a total of 904,908 prevalent cases of MS in the 10MM, and by 2023 GlobalData epidemiologists forecast that the number of prevalent cases will grow to 940,413 prevalent cases. During the forecast period, India will have the highest annual growth rate (AGR) at 1.99%, Spain will have the second highest (AGR: 1.05%), and China will have the third highest (AGR: 0.93%).

Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/epicast-report-multiple-sclerosis-epidemiology-forecast-to-2023

GlobalData epidemiologists used country-specific sources published by peer-reviewed journals to estimate the incidence and prevalence of MS in each of the 10MM. To provide a thorough description of the MS patient population in each country, GlobalData epidemiologists segmented MS incident and prevalent cases by age and sex, both of which strongly affect the epidemiology of MS. Moreover, cases are segmented into three common sub-types: relapsing-remitting MS, primary progressive MS, and secondary progressive MS. A major strength of this analysis is that the forecast methodology was consistent across the 10MM to allow for a meaningful comparison of the patient populations in each country.

Scope

- The Multiple Sclerosis (MS) EpiCast Report provides an overview of the risk factors and comorbidities, and global and historical trends of MS in the 10 major markets (10MM) (the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India). It includes a 10-year epidemiological forecast of MS prevalent and incident cases segmented by sex and age (in five-year increments beginning at 20 years and ending at =85 years) in these markets.
- The MS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/198412

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global MS market.
- Quantify patient populations in the global MS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for MS therapeutics in each of the markets covered.

Contact US:

Office: United States

State Tower 90 State Street, Suite 700 Albany, NY 12207 United States Toll Free: 866-997-4948 Tel: +1-518-618-1030 E: sales@marketresearchreports.biz

Blog: http://mresearchreports.blogspot.com/

Emerging Unconventional Resources Overview - Regulatory Environment, Industry Developments and Key Challenges

Summary

"Emerging Unconventional Resources Overview - Regulatory Environment, Industry Developments and Key Challenges" is the latest report from GlobalData, the oil and gas industry analysis specialist, to examine the emerging markets for the development of unconventional resources outside the US. The report analyses shale developments in Poland, Argentina, China and Australia; Coal Bed Methane (CBM) and Coal Seam Gas (CSG) developments in China and Australia; oil sands development in Canada, and extra-heavy oil development in Venezuela. It has been compiled using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalDatas team of industry experts.

Visit Complete Report Here:  http://www.marketresearchreports.biz/analysis-details/emerging-unconventional-resources-overview-regulatory-environment-industry-developments-and-key-challenges

Scope

The report provides information and analysis on emerging markets for the development of unconventional resources outside the US. It primarily includes -
- Overview of and updates on shale oil and shale gas resources, developments, and challenges in Poland, Argentina, China and Australia
- Analysis of the CBM and CSG industries in China and Australia
- Overview of and developments and key challenges in the oil sands industry in Canada
- Update on resources, development and challenges for extra-heavy oil development in Venezuela

Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/198411

Reasons to buy

The report will enhance your decision-making capabilities by allowing you to -
- Determine the resource potential of unconventional resources in key countries outside the US
- Stay abreast of developments in unconventional resources in major emerging markets
- Identify opportunities and challenges in emerging unconventional resources markets
- Gain an insight into financial deal activity (mergers, acquisitions and asset transactions) for unconventional resources in these emerging markets in recent years

Contact US:

Office: United States

State Tower 90 State Street, Suite 700 Albany, NY 12207 United States Toll Free: 866-997-4948 Tel: +1-518-618-1030 E: sales@marketresearchreports.biz

Blog: http://mresearchreports.blogspot.com/

Eladur (Neuropathic Pain) - Forecast and Market Analysis to 2022

Summary

Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability.

Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/eladur-neuropathic-pain-forecast-and-market-analysis-to-2022

New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.

Eladur is a transdermal bupivacaine patch developed by Durect Corporation that is intended to deliver bupivacaine for up to three days from a single application. Durect had been engaged in a licensing agreement with Pfizer (through its subsidiary, King Pharmaceuticals) to develop and commercialize Eladur, but in February 2012, Pfizer notified Durect that it was terminating this agreement and returned all the rights to Durect. In January 2014, Durect established another development and commercialization agreement for Eladur, this time with Impax Laboratories.

Scope

- Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Eladur acetate including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Eladur acetate for the top six countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain and the UK.

Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/198422

ff
Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Neuropathic pain
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Eladur acetate performance
- Obtain sales forecast for Eladur acetate from 2012-2022 in the top six countries (the US, France, Germany, Italy, Spain and the UK).

Contact US:

Office: United States

State Tower 90 State Street, Suite 700 Albany, NY 12207 United States Toll Free: 866-997-4948 Tel: +1-518-618-1030 E: sales@marketresearchreports.biz

Blog: http://mresearchreports.blogspot.com/

DS5565 (Neuropathic Pain) - Forecast and Market Analysis to 2022

Summary

Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability.

Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/ds5565-neuropathic-pain-forecast-and-market-analysis-to-2022

New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.

DS-5565 is an oral, small-molecule analgesic being developed by Daiichi Sankyo for the treatment of PDN. It is a voltage-dependent calcium channel alpha-2-delta ligand, meaning that it has a mechanism of action similar to Lyrica and gabapentin, and reduces pain through the inhibition of calcium channel-associated currents. These compounds bind to the a-2-d subunits (a-2-d-1 and a-2-d-2) of voltage-dependent calcium channels, where the a-2-d-1 subunit is the main target for the analgesic effect of a-2-d ligands, while the a-2-d-2 subunit is thought to contribute to the CNS side effects of a-2-d ligands, although this has not been fully demonstrated (Yokoyama et al., 2013).

Download Full Report with TOC:  http://www.marketresearchreports.biz/sample/sample/198421

Scope

- Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on DS-5565 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for DS-5565 for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Neuropathic pain
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of DS-5565 performance
- Obtain sales forecast for DS-5565 from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).

Contact US:

Office: United States

State Tower 90 State Street, Suite 700 Albany, NY 12207 United States Toll Free: 866-997-4948 Tel: +1-518-618-1030 E: sales@marketresearchreports.biz

Blog: http://mresearchreports.blogspot.com/

Diffuse Diabetic Macular Edema Global Clinical Trials Review, H1, 2014

Summary

Clinical trial report, Diffuse Diabetic Macular Edema Global Clinical Trials Review, H1, 2014" provides data on the Diffuse Diabetic Macular Edema clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diffuse Diabetic Macular Edema. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diffuse Diabetic Macular Edema. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by team of industry experts.

Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/diffuse-diabetic-macular-edema-global-clinical-trials-review-h1-2014

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/198430

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Contact US:

Office: United States

State Tower 90 State Street, Suite 700 Albany, NY 12207 United States Toll Free: 866-997-4948 Tel: +1-518-618-1030 E: sales@marketresearchreports.biz

Blog: http://mresearchreports.blogspot.com/

Diabetic Peripheral Neuropathy Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, Diabetic Peripheral Neuropathy Global Clinical Trials Review, H1, 2014" provides data on the Diabetic Peripheral Neuropathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Peripheral Neuropathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Peripheral Neuropathy. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by  team of industry experts.

Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/diabetic-peripheral-neuropathy-global-clinical-trials-review-h1-2014

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/198429

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Contact US:

Office: United States

State Tower 90 State Street, Suite 700 Albany, NY 12207 United States Toll Free: 866-997-4948 Tel: +1-518-618-1030 E: sales@marketresearchreports.biz

Blog: http://mresearchreports.blogspot.com/

Cymbalta (Neuropathic Pain) - Forecast and Market Analysis to 2022

Summary

Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability.

Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/cymbalta-neuropathic-pain-forecast-and-market-analysis-to-2022

New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.

Cymbalta (duloxetine) is an SNRI that was developed by Eli Lilly and was initially approved in the US in August 2004 for the treatment of major depressive disorder (MDD). The drug was later approved for PDN in September 2004. Since then, Eli Lilly has accrued multiple indications for Cymbalta, such as GAD, fibromyalgia, and most recently, for the treatment of chronic musculoskeletal pain, including chronic osteoarthritis pain and chronic low back pain.

Scope

- Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Cymbalta including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Cymbalta for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/198416

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Neuropathic pain
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Cymbalta performance
- Obtain sales forecast for Cymbalta from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).

Contact US:

Office: United States

State Tower 90 State Street, Suite 700 Albany, NY 12207 United States Toll Free: 866-997-4948 Tel: +1-518-618-1030 E: sales@marketresearchreports.biz

Blog: http://mresearchreports.blogspot.com/